V1RH14 Inhibitors
V1RH14 inhibitors represent a chemical class designed to selectively interact with and modulate the activity of the V1RH14 receptor, a protein structure that may be implicated in various biochemical pathways. The design of V1RH14 inhibitors typically stems from a deep understanding of the receptor's binding sites, conformational flexibility, and the signaling mechanisms it controls. Scientists employ techniques such as high-throughput screening, molecular modeling, and structure-activity relationship (SAR) studies to identify and optimize molecules capable of binding to this receptor with high specificity. The inhibitors in this class may vary widely in their chemical structure, ranging from small organic molecules to larger, more complex biologics.
The development of V1RH14 inhibitors necessitates a multidisciplinary approach, combining organic chemistry, biochemistry, and pharmacology, among other fields. The inhibitors are crafted to fit precisely into the receptor's active site, effectively blocking or modulating the receptor's natural ligands from exerting their normal activity. This involves creating a compound that can maintain a high affinity for the receptor while exhibiting stability within the biological environment. The physical and chemical properties such as solubility, stability, and permeability are meticulously adjusted to ensure that these molecules can reach the receptor in adequate concentrations. V1RH14 inhibitors are characterized by their binding kinetics, which describe how quickly and tightly they interact with the receptor, and by their selectivity, which ensures that they do not significantly affect other receptors in the body, thereby minimizing off-target effects.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound is a selective inhibitor of p38 MAPK, a protein kinase involved in inflammatory responses and stress-induced signaling. By inhibiting p38 MAPK, SB203580 can indirectly reduce the activity of V1RH14 if V1RH14 is a downstream effector in the p38 MAPK signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is pivotal for various cellular functions including cell growth and survival. Inhibition of PI3K can lead to a decrease in AKT phosphorylation and activity. If V1RH14 activity is AKT-dependent, then LY294002 could lead to its functional inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
This compound selectively inhibits MEK1/2, which are upstream activators of ERK1/2 in the MAPK/ERK pathway. If V1RH14 functions are regulated via the ERK signaling, PD98059 would indirectly reduce its activity by preventing ERK phosphorylation and activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK (c-Jun N-terminal kinases), SP600125 can disrupt the JNK signaling pathway. If V1RH14 is regulated by JNK pathway components, the use of SP600125 could lead to inhibition of V1RH14 activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is known to inhibit NF-κB activation by blocking the phosphorylation of IκBα. If V1RH14 activity is modulated by NF-κB signaling, this compound could indirectly lead to its inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR signaling is crucial for cell growth and proliferation. Inhibition of mTOR by Rapamycin could affect the activity of V1RH14 if it is part of the mTOR signaling network. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another inhibitor of MEK1/2, thus also potentially reducing ERK1/2 activity. If V1RH14 is downstream of the MEK/ERK pathway, its activity will likely be diminished by U0126. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Similar to LY294002, it could reduce V1RH14 activity by disrupting PI3K/AKT signaling if V1RH14 is dependent on this pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
This compound is a selective inhibitor of ROCK (Rho-associated protein kinase), which plays a role in regulating cytoskeleton dynamics. If V1RH14 is involved in pathways regulated by ROCK, Y-27632 may result in its inhibition. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML7 is known to inhibit myosin light chain kinase (MLCK), which is involved in muscle contraction and cellular motility. If the function of V1RH14 is linked to MLCK-mediated processes, ML7 could indirectly inhibit V1RH14. | ||||||